4. For each relevant country, the volatility adjustment to the risk-free interest rates referred to in paragraph 3 for the currency of that country shall, before application of the 65 % factor, be increased by the difference between the risk-corrected country spread and twice the risk-corrected currency spread, whenever that difference is positive and the risk-corrected country spread is higher than 100 basis points.

We generally share core values, but the difference in our position on the death penalty, which I am proud to say is entirely banned in Europe, makes our joint voice less effective and less credible in the world.

Hedging or diversification effects associated with long and short positions involving different instruments or different securities of the same obligor, as well as long and short positions in different issuers, may only be recognised by explicitly modelling gross long and short positions in the different instruments.

Nevertheless, differences remain on which I have supported the positions of the rapporteur, which were supported, incidentally, by the specialised committee: on the one hand, when an incident that is reported is due to gross negligence, the Member States must be able to take legal action; on the other, what was Article 9 in the version originally proposed by the Commission, dealing with confidential reporting, must be maintained because the ‘disidentification’ of reporting in this area is often crucial to a better understanding of the factors that can influence the occurrenc ...[+++]e of air accidents.

Where the agreement reached by the Member States represented within the coordination group or the position of the majority of the Member States represented within the coordination group differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the coordination group shall attach to the agreement or majority position a detailed explanation of the scientific grounds for the differences together with the recommendation.

Where the agreement reached by the Member States represented within the coordination group or the position of the majority of Member States differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the coordination group shall attach to the agreement or the majority position a detailed explanation of the scientific grounds for the differences together with the recommendation.